In view of the above, the increase of plasma omentin-1 concentration in patients with type 2 diabetes after a six-month insulin treatment seems to be the result of beneficial influence of the applied therapy in terms of the compensation of metabolic disorders accompanying obesity and co-participating in the pathomechanism of the disease. Here, INS is linked to Obesity.